Clifford Swan Investment Counsel LLC Has $29.23 Million Holdings in Corteva, Inc. (NYSE:CTVA)

Clifford Swan Investment Counsel LLC lifted its holdings in Corteva, Inc. (NYSE:CTVAFree Report) by 0.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 513,122 shares of the company’s stock after acquiring an additional 515 shares during the quarter. Corteva makes up approximately 1.1% of Clifford Swan Investment Counsel LLC’s holdings, making the stock its 24th largest holding. Clifford Swan Investment Counsel LLC owned about 0.07% of Corteva worth $29,227,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Pinnacle Associates Ltd. lifted its holdings in Corteva by 13.3% during the 3rd quarter. Pinnacle Associates Ltd. now owns 28,117 shares of the company’s stock worth $1,653,000 after buying an additional 3,309 shares in the last quarter. JFS Wealth Advisors LLC lifted its holdings in Corteva by 184.9% during the 3rd quarter. JFS Wealth Advisors LLC now owns 1,513 shares of the company’s stock worth $89,000 after buying an additional 982 shares in the last quarter. Gladstone Institutional Advisory LLC lifted its holdings in Corteva by 49.6% during the 3rd quarter. Gladstone Institutional Advisory LLC now owns 10,421 shares of the company’s stock worth $613,000 after buying an additional 3,457 shares in the last quarter. Farther Finance Advisors LLC lifted its holdings in Corteva by 26.5% during the 3rd quarter. Farther Finance Advisors LLC now owns 4,210 shares of the company’s stock worth $248,000 after buying an additional 881 shares in the last quarter. Finally, Pure Financial Advisors LLC acquired a new position in Corteva during the 3rd quarter worth $217,000. 81.54% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Corteva news, insider Brian Titus sold 26,560 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $63.74, for a total transaction of $1,692,934.40. Following the completion of the transaction, the insider now owns 11,347 shares in the company, valued at approximately $723,257.78. This represents a 70.07 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 0.14% of the company’s stock.

Corteva Price Performance

CTVA opened at $62.96 on Friday. The company has a quick ratio of 0.93, a current ratio of 1.45 and a debt-to-equity ratio of 0.08. Corteva, Inc. has a 12 month low of $50.01 and a 12 month high of $66.24. The company has a fifty day simple moving average of $61.34 and a 200 day simple moving average of $59.28. The stock has a market cap of $43.16 billion, a P/E ratio of 48.81, a P/E/G ratio of 1.68 and a beta of 0.78.

Corteva (NYSE:CTVAGet Free Report) last released its quarterly earnings data on Wednesday, February 5th. The company reported $0.32 EPS for the quarter, missing analysts’ consensus estimates of $0.34 by ($0.02). Corteva had a net margin of 5.36% and a return on equity of 7.19%. On average, research analysts expect that Corteva, Inc. will post 2.96 EPS for the current year.

Corteva declared that its board has approved a share buyback program on Tuesday, November 19th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the company to repurchase up to 7.5% of its stock through open market purchases. Stock buyback programs are often an indication that the company’s board of directors believes its stock is undervalued.

Corteva Announces Dividend

The company also recently announced a quarterly dividend, which will be paid on Monday, March 17th. Shareholders of record on Monday, March 3rd will be issued a dividend of $0.17 per share. This represents a $0.68 dividend on an annualized basis and a yield of 1.08%. The ex-dividend date of this dividend is Monday, March 3rd. Corteva’s dividend payout ratio (DPR) is presently 52.71%.

Analysts Set New Price Targets

Several research firms have issued reports on CTVA. Barclays upped their price objective on Corteva from $62.00 to $64.00 and gave the stock an “equal weight” rating in a report on Tuesday, January 21st. BNP Paribas raised Corteva to a “hold” rating in a research note on Monday, February 10th. Bank of America increased their price target on Corteva from $69.00 to $73.00 and gave the company a “buy” rating in a research note on Tuesday, February 11th. UBS Group cut their price target on Corteva from $74.00 to $73.00 and set a “buy” rating on the stock in a research note on Friday, January 10th. Finally, KeyCorp increased their price target on Corteva from $68.00 to $70.00 and gave the company an “overweight” rating in a research note on Friday, February 7th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, Corteva presently has a consensus rating of “Moderate Buy” and an average target price of $67.79.

Read Our Latest Analysis on CTVA

Corteva Profile

(Free Report)

Corteva, Inc operates in the agriculture business. It operates through two segments, Seed and Crop Protection. The Seed segment develops and supplies advanced germplasm and traits that produce optimum yield for farms. It offers trait technologies that enhance resistance to weather, disease, insects, and herbicides used to control weeds, as well as food and nutritional characteristics.

Read More

Want to see what other hedge funds are holding CTVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Corteva, Inc. (NYSE:CTVAFree Report).

Institutional Ownership by Quarter for Corteva (NYSE:CTVA)

Receive News & Ratings for Corteva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Corteva and related companies with MarketBeat.com's FREE daily email newsletter.